Atherosclerosis
Volume 211, Issue 1 , Pages 237-241, July 2010

Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine☆

  • Dan-yan Xu

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • Corresponding Author InformationCorresponding authors at: 139 Middle Renming Road, Department of Cardiology, Internal Medicine, Second Xiangya Hospital, Changsha, Hunan 410011, PR China. Tel.: +86 731 5292100; fax: +86 731 4895989.
    • ,
  • Jun Shu

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Quan-yue Huang

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Binaya Wasti

      Affiliations

    • Department of Respiratory Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Chen Chen

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Ling Liu

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • ,
  • Shui-ping Zhao

      Affiliations

    • Department of Internal Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China
    • Corresponding Author InformationCorresponding authors at: 139 Middle Renming Road, Department of Cardiology, Internal Medicine, Second Xiangya Hospital, Changsha, Hunan 410011, PR China. Tel.: +86 731 5292100; fax: +86 731 4895989.

Received 28 August 2009; received in revised form 27 January 2010; accepted 27 January 2010. published online 02 March 2010.

Abstract 

Objectives

To evaluate the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy of the Chinese traditional medicine Zhibitai in subjects with moderate to high cardiovascular risk.

Methods

A total of 169 subjects (96 males and 73 females, aged 55–72) having moderate to high cardiovascular risk were recruited and randomly divided into Zhibitai group (n=85), which received 480mg of Zhibitai orally twice daily, and atorvastatin group (n=84), which received 10mg of atorvastatin orally once a day. Blood lipoproteins, myocardial enzymes, liver and renal functions were measured before treatment started, and after 4 and 8 weeks of the treatment. High sensitivity C-reactive protein (hs-CRP), P-selectin, matrix metalloproteinase-9 (MMP-9) and soluble intercellular adhesion molecule-1 (sICAM-1) were measured before and after the treatment.

Results

Plasma total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were significantly decreased, and high-density lipoprotein cholesterol (HDL-C) was increased in both groups, after 4 and 8 weeks of treatment (p<0.05 for all pairs). Interestingly, plasma triglycerides (TG) decreased in the Zhibitai group after 4 weeks of treatment but only decreased in the atorvastatin group after 8 weeks. Inflammatory factors such as hs-CRP, P-selectin, MMP-9 and sICAM-1 were significantly decreased in both groups after 8 weeks (p<0.01 for all pairs). Furthermore, there was no difference in myocardial enzymes, hepatic and renal function test parameters, incidence of myopathy or gastrointestinal tract symptoms in either group.

Conclusion

Zhibitai therapy is a good alternative to statin therapy to reduce plasma cholesterol levels in subjects with moderate to high cardiovascular risk. Most importantly, Zhibitai is safe to use.

Keywords: Zhibitai, Cardiovascular risk, Inflammatory factor, Safety, Cholesterol

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ This work was supported by 2008 National Nature Scientific Funding of China (No. 30770856), 2008 Program for New Century Excellent Talents in University (NCET-08-0566) and Grant of Institute of Metabolism and Endocrine of Central South University of 2008 (DY-2008-02-04).

PII: S0021-9150(10)00092-4

doi:10.1016/j.atherosclerosis.2010.01.044

Atherosclerosis
Volume 211, Issue 1 , Pages 237-241, July 2010

Article Tools